Increased lesion detectability in patients with locally advanced breast cancer—A pilot study using dynamic whole-body [18F]FDG PET/CT

Mette Abildgaard Pedersen,André H. Dias,Karin Hjorthaug,Lars C. Gormsen,Joan Fledelius,Anna Lyhne Johnsson,Signe Borgquist,Trine Tramm,Ole Lajord Munk,Mikkel Holm Vendelbo
DOI: https://doi.org/10.1186/s13550-024-01096-4
IF: 3.434
2024-03-28
EJNMMI Research
Abstract:Accurate diagnosis of axillary lymph node (ALN) metastases is essential for prognosis and treatment planning in breast cancer. Evaluation of ALN is done by ultrasound, which is limited by inter-operator variability, and by sentinel lymph node biopsy and/or ALN dissection, none of which are without risks and/or long-term complications. It is known that conventional 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG) positron emission tomography/computed tomography (PET/CT) has limited sensitivity for ALN metastases. However, a recently developed dynamic whole-body (D-WB) [ 18 F]FDG PET/CT scanning protocol, allowing for imaging of tissue [ 18 F]FDG metabolic rate (MR FDG ), has been shown to have the potential to increase lesion detectability. The study purpose was to examine detectability of malignant lesions in D-WB [ 18 F]FDG PET/CT compared to conventional [ 18 F]FDG PET/CT.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?